Recombinant adeno-associated virus vectors in the treatment of rare diseases.
BACKGROUND
An estimated 25 million Americans are living with rare diseases. Adeno-associated virus (AAV)-mediated gene therapy is an emerging therapeutic option for the more than 7,000 identified rare diseases. This paper highlights the benefits of AAV therapy compared to conventional small molecules, discusses current pre-clinical and clinical applications of AAV-mediated gene therapy, and offers insights into cutting edge research that will shape the future of AAV for broad therapeutic use.


METHODS
In this review the biology of AAV and our ability to generate disease-specific variants is summarized. Limitations of current therapy are reviewed, with an emphasis on immune detection of virus, viral tropism and tissue targeting, and limitations of gene expression. Information for this review was found using PubMed and clinicaltrials.gov.


CONCLUSIONS
Currently the scope of clinical trials of AAV gene therapy is concentrated in an array of phase I/II safety trials with less than two dozen rare diseases featured. Pre-clinical, translational studies are expanding in number as developments within the last decade have made generation of improved AAV vectors available to more researchers. Further, one bottleneck that is being overcome is the availability of disease models, which will allow for improved preclinical testing and advancement of AAV to more clinical applications.
Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina, USA, The University of North Carolina at Chapel Hill, 7119 Thurston Bowles Building (104 Manning Drive), Campus Box 7352, Chapel Hill, NC, 27599-7352, United States.
Eric
E
Hastie
Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina, USA, The University of North Carolina at Chapel Hill, 7119 Thurston Bowles Building (104 Manning Drive), Campus Box 7352, Chapel Hill, NC, 27599-7352, United States; Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA, The University of North Carolina at Chapel Hill, 7119 Thurston Bowles Building (104 Manning Drive), Campus Box 7352, Chapel Hill, NC, 27599-7352, United States.
R Jude
RJ
Samulski
AAV; AAV vectors; Adeno-associated virus; Gene therapy; Orphan disease; Rare disease
Mol Ther. 2003 Aug;8(2):188-95
12907141
J Virol. 2002 May;76(9):4580-90
11932423
Biomaterials. 2014 Aug;35(26):7598-609
24917028
Cytotherapy. 2007;9(6):593-9
17882724
Lancet. 2014 Mar 29;383(9923):1129-37
24439297
J Clin Invest. 2013 Dec;123(12):5310-8
24231351
Mol Ther. 2015 Mar;23(3):477-87
25358252
J Virol. 2015 Jan 15;89(2):952-61
25355884
J Virol. 1998 Feb;72(2):1438-45
9445046
Expert Opin Biol Ther. 2012 Jun;12(6):757-66
22519910
J Infect Dis. 2009 Feb 1;199(3):381-90
19133809
Exp Cell Res. 2010 Nov 1;316(18):3087-92
20580709
Biores Open Access. 2012 Jun;1(3):109-14
23514839
Hum Gene Ther. 2011 Nov;22(11):1389-401
21476868
Adv Otorhinolaryngol. 2009;66:87-98
19494574
Mol Ther. 2006 May;13(5):967-75
16442848
J Virol. 2002 Dec;76(24):12900-7
12438615
Mol Ther. 2015 Jan;23(1):192-201
25322757
Hum Gene Ther. 2014 Jul;25(7):609-18
24725025
Mol Ther. 2010 Jan;18(1):80-6
19904234
Blood. 2006 Nov 15;108(10 ):3321-8
16868252
Science. 2014 Sep 19;345(6203):1505-8
25237101
Curr Pharm Biotechnol. 2014;14(12):1072-82
24678652
Gene Ther. 2009 Aug;16(8):944-52
19675584
Gene Ther. 2001 Aug;8(16):1248-54
11509958
J Virol. 2015 Jan;89(1):181-94
25320294
Mol Ther Methods Clin Dev. 2014 Feb 5;1:null
25383359
Hum Gene Ther. 2010 Jul;21(7):903-10
20163245
Mol Ther Nucleic Acids. 2014 Oct 14;3:e202
25313621
Front Immunol. 2014 Jul 23;5:350
25101090
Gene Ther. 2012 Mar;19(3):288-94
21697954
Nature. 2015 Jan 15;517(7534):360-4
25363772
Mol Ther. 2012 Feb;20(2):443-55
22068425
Hum Gene Ther. 2014 Mar;25(3):189-98
24251946
Front Immunol. 2013 Aug 30;4:261
24009613
Nat Med. 2014 May;20(5):542-7
24705334
Hum Gene Ther. 2015 May;26(5):257-65
25807962
Gene Ther. 2014 Apr;21(4):427-33
24572788
Circ Res. 2014 May 23;114(11):1827-46
24855205
J Virol. 2000 Feb;74(4):1761-6
10644347
Mol Ther. 2015 Feb;23(2):270-7
25369768
Mol Ther Nucleic Acids. 2014 Apr 29;3:e160
24781192
J Med Virol. 1999 Nov;59(3):406-11
10502275
Mol Ther. 2014 Nov;22(11):1923-35
25200009
J Gene Med. 2014 May-Jun;16(5-6):122-30
24962736
Curr Protoc Microbiol. 2012 Aug;Chapter 14:Unit14D.2
22875566
J Clin Invest. 2009 Aug;119(8):2388-98
19587448
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7827-32
18511559
J Virol. 2006 Oct;80(19):9831-6
16973587
J Biol Chem. 2001 Jun 8;276(23):20610-6
11262413
Hum Gene Ther. 2013 Nov;24(11):906-13
24164238
Clin Vaccine Immunol. 2011 Sep;18(9):1586-8
21775517
Nat Biotechnol. 1999 Feb;17(2):181-6
10052356
J Clin Invest. 2013 Jul;123(7):2994-3001
23778142
J Virol. 2014 Jan;88(2):925-36
24198403
Gene Ther. 2015 Feb;22(2):196-201
25410741
Blood. 2011 Jun 16;117(24):6459-68
21474674
Hum Mol Genet. 2013 Oct 1;22(19):3894-905
23740938
Hum Gene Ther. 2011 Oct;22(10):1239-47
21609134
Mol Ther. 2014 May;22(5):929-39
24468915
Blood. 2009 Sep 3;114(10):2077-86
19506302
J Control Release. 2005 Nov 2;108(1):161-77
16125817
J Cell Sci. 2008 Feb 1;121(Pt 3):349-57
18216333
Neurobiol Dis. 2012 Nov;48(2):179-88
22001604
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14894-9
25267637
J Virol. 2001 Aug;75(15):6884-93
11435568
N Engl J Med. 2014 Nov 20;371(21):1994-2004
25409372
J Cardiovasc Pharmacol. 2015 Feb;65(2):153-9
25295466
Mol Ther. 2010 Sep;18(9):1731-5
20606642
Front Mol Neurosci. 2014 Sep 19;7:76
25285067
Neuropsychopharmacology. 2014 Dec;39(13):3100-11
24998620
Hum Gene Ther. 2012 Jun;23(6):548-56
22642257
J Virol. 2006 Jun;80(11):5516-22
16699032
J Gene Med. 2011 Feb;13(2):114-22
21322099
Hum Gene Ther. 2015 Feb;26(2):69-81
25419787
J Biol Chem. 1993 Feb 15;268(5):3781-90
7679117
Gene Ther. 2014 Dec;21(12 ):1041-50
25273354
Hum Gene Ther. 2012 Aug;23(8):903-14
22642214
Anal Chem. 2012 Feb 7;84(3):1677-86
22242920
Expert Opin Drug Deliv. 2014 Mar;11(3):345-64
24386892
Circulation. 2004 Feb 3;109(4):513-9
14732747
Hum Gene Ther. 2015 Jan;26(1):26-35
25382056
Hum Mol Genet. 2011 Dec 1;20(23):4569-81
21880665
Hum Gene Ther. 2010 Mar;21(3):311-23
19824806
Front Immunol. 2013 Oct 18;4:341
24151496
Front Microbiol. 2011 Oct 04;2:204
22065962
Cold Spring Harb Perspect Med. 2014 Oct 09;5(2):a017392
25301933
Hum Gene Ther. 2009 Aug;20(8):796-806
19569968
PLoS One. 2014 Apr 29;9(4):e95900
24780906
Gene Ther. 2012 Jun;19(6):649-58
22357511
Front Immunol. 2014 Jan 30;5:9
24523720
Hum Mol Genet. 2011 Apr 15;20(R1):R2-6
21531790
Ann Neurol. 2010 Nov;68(5):629-38
21031578
Hum Gene Ther. 2009 Aug;20(8):861-70
19419276
Front Mol Neurosci. 2014 Apr 07;7:25
24778606
J Virol. 2012 Aug;86(15):7739-51
22593150
Mol Ther. 2011 Feb;19(2):326-34
21119620
Mol Genet Metab Rep. 2014;1:103-113
25024934
Hum Gene Ther. 2014 May;25(5):461-74
24484067
Nat Med. 2006 Mar;12(3):342-7
16474400
J Gene Med. 2008 Apr;10(4):400-11
18220318
Mol Ther. 2015 May;23(5):896-906
25592335
Hum Gene Ther. 2014 Mar;25(3):180-8
24299335
Front Mol Neurosci. 2014 Jun 02;7:50
24917785
Sci Transl Med. 2011 Jun 22;3(88):88ra54
21697530
Adv Exp Med Biol. 2014;801:687-93
24664759
Arch Ophthalmol. 2012 Jan;130(1):9-24
21911650
Nat Commun. 2014;5:3075
24435020
Gene Ther. 2014 Jul;21(7):653-61
24830434
Mol Ther. 2006 Jul;14(1):97-106
16624620
Nat Rev Genet. 2000 Nov;1(2):91-9
11253666
Hum Gene Ther. 2013 Jun;24(6):630-40
23570273
Nat Rev Genet. 2013 Oct;14(10):681-91
23999272
Mol Ther. 2014 Sep;22(9):1605-13
24954473
Nat Med. 2007 Apr;13(4):419-22
17369837
Expert Opin Biol Ther. 2011 Mar;11(3):315-27
21204741
Cell. 2014 Oct 9;159(2):440-55
25263330
PLoS One. 2014 Aug 29;9(8):e106472
25170953
Gene Ther. 2006 Jun;13(11):926-31
16482202
Hum Gene Ther Methods. 2013 Apr;24(2):59-67
23442094
Mol Ther. 2012 Jun;20(6):1131-8
22395529